# QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

> **NCT03228667** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Urothelial Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Merkel Cell Carcinoma
- Melanoma
- Renal Cell Carcinoma
- Gastric Cancer
- Cervical Cancer
- Hepatocellular Carcinoma
- Microsatellite Instability
- Mismatch Repair Deficiency
- Colorectal Cancer

## Interventions

- **DRUG:** N-803 + Pembrolizumab
- **DRUG:** N-803 + Nivolumab
- **DRUG:** N-803 + Atezolizumab
- **DRUG:** N-803 + Avelumab
- **DRUG:** N-803 + Durvalumab
- **DRUG:** N-803 + Pembrolizumab + PD-L1 t-haNK
- **DRUG:** N-803 + Nivolumab + PD-L1 t-haNK
- **DRUG:** N-803 + Atezolizumab + PD-L1 t-haNK
- **DRUG:** N-803 + Avelumab + PD-L1 t-haNK
- **DRUG:** N-803 + Durvalumab + PD-L1 t-haNK
- **DRUG:** N-803 + Docetaxel + Pembrolizumab
- **DRUG:** N-803 + Docetaxel + Nivolumab

## Key facts

- **NCT ID:** NCT03228667
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-12-11
- **Primary completion:** 2029-08-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03228667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03228667, "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03228667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*